Medicine

All Articles

Human break outs of a novel reassortant Oropouche virus in the Brazilian Amazon region

.Attributes Medication, Posted online: 18 September 2024 doi:10.1038/ s41591-024-03300-3Genomic and ...

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative bust cancer cells: a stage 2 flexible test

.PatientsPatients in accomplices An as well as B were qualified for registration if they went to min...

Targeted therapy led through circulating growth DNA review in innovative intestinal lumps

.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observ...

Countering the effect of the weather problems on wellness will definitely demand information

.As dramatically climbing international temperature levels threaten the wellness and also wellbeing ...

Exposure to extreme heat energy raises perinatal mortality in sub-Saharan Africa

.Publisheru00e2 $ s note Springer Attributes continues to be neutral for jurisdictional insurance cl...

Data- driven risk stratification and precision monitoring of pulmonary blemishes sensed on breast computed tomography

.Individual recruitmentThe retrospective main dataset made up participants coming from the MCC in th...

Datopotamab\u00e2 $ \"deruxtecan in early-stage bosom cancer: the consecutive various task randomized I-SPY2.2 phase 2 test

.Completing enthusiasms.J.L.M. states institutional analysis financing coming from AstraZeneca, Seag...

Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer along with or even without brain metastases: a phase 3b\/4 trial

.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-rando...

Progressing ASO treatments from development to application

.Competing interests.R.S., M.S., H.G. and A.A.R. are organizers of the 1M1M effort. H.G. as well as ...

Post- commendation proof generation: a common accountability for medical care

.Nature Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03241-xPost-approval ...